Monoclonal Antibodies

Bebtelovimab has not been approved, but has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

The dosage in adults (18 years and older) and pediatric patients (≥12 years of age and weighing at least 40 kg) is bebtelovimab 175 mg. Bebtelovimab should be administered as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset. Under this EUA, bebtelovimab must be administered as a single intravenous injection over at least 30 seconds.

Patients must be clinically monitored during administration and observe patients after IV infusion.

Looking for COVID test?

BOOK YOUR TEST AT OUR HAZEL CREST OFFICE

  • 3330 W 177th St.,
    Hazel Crest, IL 60429

    Book Test